NTLA Revenue Flow Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.
2026-06-30: Revenue $7.66M ; Revenue including tax (m) ; Cost of revenue (m) ; Research and development $82.59M . 2026-03-31: Revenue $15.05M ; Revenue including tax (m) ; Cost of revenue (m) ; Research and development $80.74M . 2025-12-31: Revenue $23.02M* ; Revenue including tax (m) ; Cost of revenue (m) ; Research and development $88.65M* . 2025-09-30: Revenue $13.78M ; Revenue including tax (m) ; Cost of revenue (m) ; Research and development $94.75M . Consolidation item Separate filed amounts; connecting flows are not established. Components and totals may overlap.
NTLA revenue flow Filed amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow. Operating Segments $7.66M Revenue $7.66M Operating income -$112.76M Other income, net $6.13M Research & development $82.60M Net income -$106.63M
Counterparty Name Separate filed amounts; connecting flows are not established. Components and totals may overlap.
NTLA revenue flow Filed amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow. Avencell $0.00 Kyverna Therapeutics Inc $0.00 Revenue $7.66M Operating income -$112.76M Other income, net $6.13M Research & development $82.60M Net income -$106.63M
Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.
Historical revenue and expense breakdown Revenue and expense 3 month Period end Revenue Revenue including tax Cost of revenue Research and development Income tax Net income 2026-06-30 $7.66M (m) (m) $82.59M (m) -$106.63M 2026-03-31 $15.05M (m) (m) $80.74M (m) -$96.23M 2025-12-31 $23.02M* (m) (m) $88.65M* (m) -$95.79M* 2025-09-30 $13.78M (m) (m) $94.75M (m) -$101.32M 2025-06-30 $14.24M (m) (m) $97.03M (m) -$101.25M 2025-03-31 $16.63M (m) (m) $108.43M (m) -$114.33M 2024-09-30 $9.11M (m) (m) $123.38M (m) -$135.71M 2024-06-30 $6.96M (m) (m) $114.21M (m) -$146.97M 2024-03-31 $28.93M (m) (m) $111.85M (m) -$107.44M 2023-12-31 (m) $0.00* (m) (m) (m) (m) 2023-09-30 $11.99M $1.00M (m) $113.70M (m) -$122.22M 2023-06-30 $13.59M $2.80M (m) $115.28M (m) -$123.68M 2023-03-31 $12.61M $2.80M (m) $97.12M (m) -$103.13M 2022-09-30 $13.27M $2.90M (m) $96.65M (m) -$113.23M 2022-06-30 $14.03M $2.80M (m) $90.20M (m) -$100.68M 2022-03-31 $11.25M $2.80M (m) $133.09M (m) -$146.87M 2021-09-30 $7.20M (m) (m) $60.49M (m) -$71.64M 2021-06-30 $6.55M (m) (m) $58.88M (m) -$68.81M 2021-03-31 $6.45M (m) (m) $39.28M (m) -$46.20M 2020-12-31 $6.59M (m) (m) $38.23M (m) -$42.19M 2020-09-30 $22.22M (m) (m) $39.76M (m) -$27.84M 2020-06-30 $16.26M (m) (m) $37.77M (m) -$32.39M 2020-03-31 $12.92M (m) (m) $34.65M (m) -$31.81M 2019-12-31 $10.94M (m) $0.00* $31.73M (m) -$28.28M 2019-09-30 $10.62M (m) (m) $27.51M (m) -$23.63M 2019-06-30 $11.12M (m) (m) $25.46M (m) -$25.68M 2019-03-31 $10.43M (m) $0.00 $23.71M (m) -$21.94M 2018-12-31 $7.88M (m) $0.00* $19.92M (m) -$19.07M 2018-09-30 $7.41M (m) (m) $23.24M (m) -$22.70M 2018-06-30 $7.68M (m) (m) $23.47M (m) -$22.22M 2018-03-31 $7.47M (m) (m) $22.49M (m) -$21.36M 2017-12-31 $6.67M (m) (m) $21.17M (m) -$23.96M 2017-09-30 $7.32M (m) (m) $17.48M (m) -$15.36M 2017-06-30 $5.92M (m) (m) $15.56M (m) -$15.59M 2017-03-31 $6.21M (m) (m) $13.43M (m) -$12.63M 2016-12-31 (m) (m) (m) $11.33M $0.00* -$10.56M 2016-09-30 (m) (m) (m) $7.86M $0.00 -$7.48M 2016-06-30 (m) (m) (m) $7.42M $0.00 -$6.90M 2016-03-31 (m) (m) (m) $5.22M $0.00 -$6.69M 2015-12-31 (m) (m) (m) $4.38M -$246.00K -$5.25M 2015-09-30 (m) (m) (m) $3.46M -$282.00K -$3.02M 2015-06-30 (m) (m) (m) $1.97M -$382.00K -$3.04M 2015-03-31 (m) (m) (m) $1.37M -$102.00K -$1.09M
Revenue and expense 6 month Period end Revenue Revenue including tax Cost of revenue Research and development Income tax Net income 2026-06-30 $22.71M (m) (m) $163.33M (m) -$202.87M 2025-06-30 $30.87M (m) (m) $205.46M (m) -$215.58M 2024-06-30 $35.89M (m) (m) $226.05M (m) -$254.41M 2023-06-30 $26.20M $5.70M (m) $212.39M (m) -$226.81M 2022-06-30 $25.28M $5.70M (m) $223.29M (m) -$247.55M 2021-06-30 $12.99M (m) (m) $98.16M (m) -$115.01M 2020-06-30 $29.18M (m) (m) $72.42M (m) -$64.20M 2019-06-30 $21.55M (m) $0.00 $49.17M (m) -$47.62M 2018-06-30 $15.15M (m) $0.00 $45.96M (m) -$43.58M 2017-06-30 $12.13M (m) (m) $29.00M (m) -$28.22M 2016-06-30 (m) (m) (m) $12.65M $0.00 -$13.59M 2015-06-30 (m) (m) (m) $3.34M -$484.00K -$4.13M
Revenue and expense 8 month Period end Research and development Net income 2014-12-31 $1.10M -$9.54M
Revenue and expense 9 month Period end Revenue Revenue including tax Cost of revenue Research and development Income tax Net income 2025-09-30 $44.65M (m) (m) $300.21M (m) -$316.91M 2024-09-30 $45.00M (m) (m) $349.43M (m) -$390.12M 2023-09-30 $38.19M $6.60M (m) $326.09M (m) -$349.03M 2022-09-30 $38.55M $8.50M (m) $319.94M (m) -$360.78M 2021-09-30 $20.20M (m) (m) $158.65M (m) -$186.66M 2020-09-30 $51.40M (m) (m) $112.18M (m) -$92.04M 2019-09-30 $32.17M (m) $0.00 $76.68M (m) -$71.26M 2018-09-30 $22.55M (m) $0.00 $69.20M (m) -$66.28M 2017-09-30 $19.45M (m) (m) $46.48M (m) -$43.58M 2016-09-30 (m) (m) (m) $20.51M $0.00 -$21.07M 2015-09-30 (m) (m) (m) $6.79M -$766.00K -$7.15M
Revenue and expense 12 month Period end Revenue Revenue including tax Cost of revenue Research and development Income tax Net income 2025-12-31 $67.67M (m) (m) $388.86M $0.00 -$412.69M 2024-12-31 $57.88M (m) (m) $466.31M (m) -$519.02M 2023-12-31 $36.27M $6.60M (m) $435.07M (m) -$481.19M 2022-12-31 $52.12M $11.40M (m) $419.98M (m) -$474.19M 2021-12-31 $33.05M $2.90M $0.00 $229.81M (m) -$267.89M 2020-12-31 $57.99M (m) $0.00 $150.41M (m) -$134.23M 2019-12-31 $43.10M (m) $0.00 $108.41M (m) -$474.19M 2018-12-31 $30.43M (m) $0.00 $89.11M (m) -$85.34M 2017-12-31 $26.12M (m) (m) $67.65M (m) -$67.54M 2016-12-31 $16.48M (m) (m) $31.84M $0.00 -$31.63M 2015-12-31 (m) (m) (m) $11.17M -$1.01M -$12.40M